2-oxa-5-azabicyclo[2.2.2]octane | 280-51-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 2-oxa-5-azabicyclo[2.2.2]octane
• CAS: 280-51-3
• 化学式: C₆H₁₁NO
• mdl: MFCD19220767
• 分子量: 113.159
• InChiKey: JNYWVERKQKRXSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-oxa-5-azabicyclo[2.2.2]octane 在 potassium fluoride 、 potassium phosphate 、 [(di(1-adamantyl)-butylphosphine)-2-(2-amino-1,1-biphenyl)]palladium(II) methanesulfonate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 水 、 二甲基亚砜 、 甲苯 为溶剂， 反应 21.0h， 生成
  参考文献：
  名称：

  [EN] BICYCLIC DERIVATIVES AND USE THEREOF
  [FR] DÉRIVÉS BICYCLIQUES ET LEUR UTILISATION

  摘要：

  A compound of Formula (I), (II) or (III), stereoisomer thereof, pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the stereoisomer are disclosed.

  公开号：

  WO2023020523A1
• 作为产物：
  描述：

  2-oxa-5-aza-bicyclo[2.2.2]octan-6-one 以84%的产率得到2-oxa-5-azabicyclo[2.2.2]octane
  参考文献：
  名称：

  Substituted benzothiazole amide derivatives

  摘要：

  公式I的化合物和一种治疗疾病的方法，与调节腺苷A2受体系统有关，包括给需要此类治疗的人口服公式1的化合物。

  公开号：

  US20030149036A1

文献信息

• [EN] SELF-IMMOLATIVE LINKERS CONTAINING MANDELIC ACID DERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF<br/>[FR] LIEURS AUTO-IMMOLABLES CONTENANT DES DÉRIVÉS D'ACIDE MANDÉLIQUE, CONJUGUÉS MÉDICAMENT-LIGAND POUR THÉRAPIES CIBLÉES, ET LEURS UTILISATIONS
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2015038426A1

  公开（公告）日：2015-03-19

  The invention provides a therapeutic drug and targeting conjugate, pharmaceutical compositions containing these conjugates in pharmaceutical composition, and uses of these conjugates in anti-neoplastic and other therapeutic regimens. Also provided are novel intermediates thereof. The conjugates provide a therapeutic drug fragment or prodrug fragment bound to a targeting moiety via a linker which comprises a substrate cleavable by a protease such as Cathepsin B. The targeting moiety is a ligand which targets a cell surface molecule, such as a cell surface receptor on an anti-neoplastic cell. The ligand may function solely as a targeting moiety or may itself have a therapeutic effect. Following administration of the therapeutic drug and targeting conjugate of formula I and exposure of the conjugate to the protease specific for the substrate, the linker is cleaved and the targeting moiety is separated from the conjugate, which causes the drug fragment or prodrug fragment to convert to the drug or prodrug. The recited conjugates are useful in anti-neoplastic therapies. Also provided are methods of making the therapeutic drug and targeting conjugates and intermediates thereof, and kits comprising the therapeutic drug and targeting conjugates.

  该发明提供了一种治疗药物和靶向共轭物，包含这些共轭物的药物组合物，以及这些共轭物在抗肿瘤和其他治疗方案中的用途。还提供了其新颖的中间体。这些共轭物通过一个由蛋白酶如半胱氨酸蛋白酶B可切割的底物组成的连接物将治疗药物片段或前药片段与靶向基团结合。靶向基团是一个以细胞表面分子为靶点的配体，例如抗肿瘤细胞上的细胞表面受体。该配体可能仅作为靶向基团，也可能本身具有治疗效果。在给药公式I的治疗药物和靶向共轭物并使共轭物暴露于特异于底物的蛋白酶的情况下，连接物被切割，靶向基团与共轭物分离，导致药物片段或前药片段转化为药物或前药。所述的共轭物在抗肿瘤疗法中很有用。还提供了制备治疗药物和靶向共轭物及其中间体的方法，以及包含治疗药物和靶向共轭物的试剂盒。
• Substituted Amino-Pyrimidine Derivatives
  申请人：Endo Pharmaceuticals Inc.

  公开号：US20140038952A1

  公开（公告）日：2014-02-06

  The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新型的取代喹唑啉和吡啶并嘧啶化合物及其药用可接受的盐、前药和溶剂化合物。还提供了制备这些化合物的方法。通过向患者投予一种或多种化合物的治疗有效量，这些化合物在共同调节PI3K和/或mTOR活性方面是有用的。通过这样做，这些化合物在治疗与PI3K/AKT/mTOR途径失调相关的疾病方面是有效的。有利的是，这些化合物作为双重PI3K/mTOR抑制剂发挥作用。可以使用这些化合物治疗各种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20160376283A1

  公开（公告）日：2016-12-29

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

  本发明涉及式I化合物及其药用可接受的组合物，用作TBK/IKKε抑制剂。
• [EN] COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035360A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula (I), or a pharmaceutically acceptable salt or composition thereof The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

  化合物、使用方法和制备抑制补体因子D的方法，包括式（I）的药用盐或其组合物。本文描述的抑制剂针对因子D并抑制或调节补体级联反应。本文描述的因子D的抑制剂减少了过度激活的补体。
• 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
  申请人：Bursavich Matthew Gregory

  公开号：US20100015141A1

  公开（公告）日：2010-01-21

  The invention relates to 4,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine compounds, including 4-phenoxy-6-aryl-1H-pyrazolo[3,4-d]pyrimidine and N-aryl-6-aryl-1H-pyrazolo[3,4-d]pyrimidin-4-amine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

  本发明涉及4,6-二取代-1H-吡唑[3,4-d]嘧啶-4-胺化合物，包括4-苯氧基-6-芳基-1H-吡唑[3,4-d]嘧啶和N-芳基-6-芳基-1H-吡唑[3,4-d]嘧啶-4-胺的化合物，其化学式为I： 或其药用可接受盐，其中组成变量如本文所述，包含该化合物的组合物，以及制造和使用这些化合物的方法。